Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22079
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiamopoulos, K. C.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorDardamanis, M.en
dc.contributor.authorSferopoulos, G.en
dc.contributor.authorPappas, M.en
dc.date.accessioned2015-11-24T19:21:02Z-
dc.date.available2015-11-24T19:21:02Z-
dc.identifier.issn0160-2446-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22079-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectCalcium Channel Blockers/*pharmacology/therapeutic useen
dc.subjectDihydropyridines/*pharmacology/therapeutic useen
dc.subjectFemaleen
dc.subjectHemodynamics/drug effectsen
dc.subjectHumansen
dc.subjectHypertension/*drug therapyen
dc.subjectIsradipineen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectRenal Circulation/*drug effectsen
dc.titleEffects of isradipine on hypertension and renal hemodynamicsen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/1376846-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate1992-
heal.abstractThe safety and efficacy of isradipine as well as its long-term effects on renal hemodynamics were evaluated in a study of 17 patients with mild-to-moderate essential hypertension and normal or slightly impaired renal function. After a 4-week placebo period, isradipine was administered according to a schedule of increasing dosages ranging from 1.25 to 5 mg twice daily. During treatment and at the latest follow-up (at 6 months), isradipine was found to lower blood pressure (diastolic and systolic) significantly. There were no significant side effects or changes in blood chemistry during treatment. Plasma renin activity and serum aldosterone were slightly raised whereas the glomerular filtration rate, renal plasma flow, and filtration fraction were significantly raised at the latest follow-up compared with the pretreatment levels.en
heal.journalNameJ Cardiovasc Pharmacolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons